All blog posts
Showing 12 out of 93 results
26 agosto 2026
Pharma M&A is back - H1 2026 Update
14 julio 2026
The EU Commission's new draft merger guidelines - key takeaways for pharma companies
16 junio 2026
2026 sees China's biotech scene continuing its ascent – but could US developments mean clouds on the horizon?
27 abril 2026
The EU Pharma Package is finally here – here's the settled position on key areas
12 marzo 2026
Snapshot: Key European pharma regulatory, IP and competition developments from 2025 for the pharmaceutical sector
15 diciembre 2025
A new era for EU pharmaceutical law: political agreement reached on the reform
09 diciembre 2025
Preserving the status quo: Boehringer Ingelheim awarded interim injunction
15 octubre 2025
Venture investment in life sciences – Activity update & outlook (US & Europe)
24 septiembre 2025
Biopharma M&A activity – strategics continue to lead the way
28 agosto 2025
The Thursday Investment Club: The case for later living
18 agosto 2025
Pharma remains an enforcement focus in China – SAMR orders unwinding of a completed pharma deal
31 julio 2025
EU Regulatory Reform for Medicinal Products: Bolar exemption
Showing 12 out of 93 results
View moreKey contacts
Laura Orlando
Managing Partner, Milan Office, Milan
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London